Single‐center study on SARS‐CoV‐2 infection in patients affected by CML: Vaccination status and bosutinib therapy as possible protective factors for hospitalization
Abstract Introduction COVID‐19 pandemic had a considerable impact among haematological patients. On the other hand, the effect of this disease on patients (pts) affected by Chronic Myeloid Leukemia (CML) is not clearly defined. Objectives The primary objective of this study was to evaluate mortality...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-04-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5923 |
| _version_ | 1827951724242927616 |
|---|---|
| author | Ivan Civettini Laura Antolini Filippo Brioschi Giovanni Paolo Maria Zambrotta Veronica Guglielmana Carlo Gambacorti‐Passerini |
| author_facet | Ivan Civettini Laura Antolini Filippo Brioschi Giovanni Paolo Maria Zambrotta Veronica Guglielmana Carlo Gambacorti‐Passerini |
| author_sort | Ivan Civettini |
| collection | DOAJ |
| description | Abstract Introduction COVID‐19 pandemic had a considerable impact among haematological patients. On the other hand, the effect of this disease on patients (pts) affected by Chronic Myeloid Leukemia (CML) is not clearly defined. Objectives The primary objective of this study was to evaluate mortality‐hospitalization rates and possible protective factors for hospitalization in CML pts affected by COVID. Methods We collected data from CML patients followed at our institution whotested positive for SARS‐CoV‐2 infection. The following variables were assessed: demographical data, type of TKI therapy, vaccination status, presence of cardiovascular disease (CVD), period of infection, COVID‐19 presenting symptoms, severity and mortality. Data were collected retrospectively and then analysed in univariate and multivariate analysis. Results Out of a total of 325 CML pts treated at our institution, we recorded 72 SARS‐CoV‐2pts (22%) who tested positive with a SARS‐CoV‐2 PCR assay. Twenty two were infected in 2020 (30%), 16 patients in 2021 (22%) and 34 in 2022 (46%); with a hospitalization rate of 27%, 25% and 3% respectively. Of the 72 confirmed infections, 13 pts (18%; (CI) 10–28) were asymptomatic and 48 (66%; CI: 55–76) had mild symptoms. A total of 11 pts were admitted to hospital and 3 of these required ICU admission. No deaths were recorded. The probability of hospitalization was significantly reduced if patients were vaccinated (odds ratio OR 0.037 with CI: 0–0.33 p 0.002) or treated with Bosutinib (OR 0.06 with CI: 0–0.5 p 0.008). Conclusion In the present study, no significant increase in mortality was noted among patients with CML as compared to the general population inItaly. Vaccination and treatment with bosutinib were identified as baseline characteristics that were associated with a decreased risk of hospitalitazion resulting from COVID‐19 infection. |
| first_indexed | 2024-04-09T13:45:46Z |
| format | Article |
| id | doaj.art-3b937b9f937f44e088f8331dc79d9e7e |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-09T13:45:46Z |
| publishDate | 2023-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-3b937b9f937f44e088f8331dc79d9e7e2023-05-09T04:04:19ZengWileyCancer Medicine2045-76342023-04-011289662966710.1002/cam4.5923Single‐center study on SARS‐CoV‐2 infection in patients affected by CML: Vaccination status and bosutinib therapy as possible protective factors for hospitalizationIvan Civettini0Laura Antolini1Filippo Brioschi2Giovanni Paolo Maria Zambrotta3Veronica Guglielmana4Carlo Gambacorti‐Passerini5Department of Medicine and Surgery University of Milano‐Bicocca Monza ItalyDepartment of Medicine and Surgery University of Milano‐Bicocca Monza ItalyHematology Division San Gerardo Hospital, ASST Monza Monza ItalyDepartment of Medicine and Surgery University of Milano‐Bicocca Monza ItalyDepartment of Medicine and Surgery University of Milano‐Bicocca Monza ItalyDepartment of Medicine and Surgery University of Milano‐Bicocca Monza ItalyAbstract Introduction COVID‐19 pandemic had a considerable impact among haematological patients. On the other hand, the effect of this disease on patients (pts) affected by Chronic Myeloid Leukemia (CML) is not clearly defined. Objectives The primary objective of this study was to evaluate mortality‐hospitalization rates and possible protective factors for hospitalization in CML pts affected by COVID. Methods We collected data from CML patients followed at our institution whotested positive for SARS‐CoV‐2 infection. The following variables were assessed: demographical data, type of TKI therapy, vaccination status, presence of cardiovascular disease (CVD), period of infection, COVID‐19 presenting symptoms, severity and mortality. Data were collected retrospectively and then analysed in univariate and multivariate analysis. Results Out of a total of 325 CML pts treated at our institution, we recorded 72 SARS‐CoV‐2pts (22%) who tested positive with a SARS‐CoV‐2 PCR assay. Twenty two were infected in 2020 (30%), 16 patients in 2021 (22%) and 34 in 2022 (46%); with a hospitalization rate of 27%, 25% and 3% respectively. Of the 72 confirmed infections, 13 pts (18%; (CI) 10–28) were asymptomatic and 48 (66%; CI: 55–76) had mild symptoms. A total of 11 pts were admitted to hospital and 3 of these required ICU admission. No deaths were recorded. The probability of hospitalization was significantly reduced if patients were vaccinated (odds ratio OR 0.037 with CI: 0–0.33 p 0.002) or treated with Bosutinib (OR 0.06 with CI: 0–0.5 p 0.008). Conclusion In the present study, no significant increase in mortality was noted among patients with CML as compared to the general population inItaly. Vaccination and treatment with bosutinib were identified as baseline characteristics that were associated with a decreased risk of hospitalitazion resulting from COVID‐19 infection.https://doi.org/10.1002/cam4.5923bosutinibchronic myeloid leukemiaCOVIDhematologymyeloproliferative neoplasmsSARS‐CoV‐2 |
| spellingShingle | Ivan Civettini Laura Antolini Filippo Brioschi Giovanni Paolo Maria Zambrotta Veronica Guglielmana Carlo Gambacorti‐Passerini Single‐center study on SARS‐CoV‐2 infection in patients affected by CML: Vaccination status and bosutinib therapy as possible protective factors for hospitalization Cancer Medicine bosutinib chronic myeloid leukemia COVID hematology myeloproliferative neoplasms SARS‐CoV‐2 |
| title | Single‐center study on SARS‐CoV‐2 infection in patients affected by CML: Vaccination status and bosutinib therapy as possible protective factors for hospitalization |
| title_full | Single‐center study on SARS‐CoV‐2 infection in patients affected by CML: Vaccination status and bosutinib therapy as possible protective factors for hospitalization |
| title_fullStr | Single‐center study on SARS‐CoV‐2 infection in patients affected by CML: Vaccination status and bosutinib therapy as possible protective factors for hospitalization |
| title_full_unstemmed | Single‐center study on SARS‐CoV‐2 infection in patients affected by CML: Vaccination status and bosutinib therapy as possible protective factors for hospitalization |
| title_short | Single‐center study on SARS‐CoV‐2 infection in patients affected by CML: Vaccination status and bosutinib therapy as possible protective factors for hospitalization |
| title_sort | single center study on sars cov 2 infection in patients affected by cml vaccination status and bosutinib therapy as possible protective factors for hospitalization |
| topic | bosutinib chronic myeloid leukemia COVID hematology myeloproliferative neoplasms SARS‐CoV‐2 |
| url | https://doi.org/10.1002/cam4.5923 |
| work_keys_str_mv | AT ivancivettini singlecenterstudyonsarscov2infectioninpatientsaffectedbycmlvaccinationstatusandbosutinibtherapyaspossibleprotectivefactorsforhospitalization AT lauraantolini singlecenterstudyonsarscov2infectioninpatientsaffectedbycmlvaccinationstatusandbosutinibtherapyaspossibleprotectivefactorsforhospitalization AT filippobrioschi singlecenterstudyonsarscov2infectioninpatientsaffectedbycmlvaccinationstatusandbosutinibtherapyaspossibleprotectivefactorsforhospitalization AT giovannipaolomariazambrotta singlecenterstudyonsarscov2infectioninpatientsaffectedbycmlvaccinationstatusandbosutinibtherapyaspossibleprotectivefactorsforhospitalization AT veronicaguglielmana singlecenterstudyonsarscov2infectioninpatientsaffectedbycmlvaccinationstatusandbosutinibtherapyaspossibleprotectivefactorsforhospitalization AT carlogambacortipasserini singlecenterstudyonsarscov2infectioninpatientsaffectedbycmlvaccinationstatusandbosutinibtherapyaspossibleprotectivefactorsforhospitalization |